Meng Xu


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.


Meng Xu is a litigator who focuses her practice on intellectual property and technology matters. Meng is also registered to practice before the US Patent and Trademark Office.

Meng’s background is in pharmaceutical sciences. She has many years of research experience in pharmacokinetic studies and drug analysis. Meng’s extensive technical experience allows her to understand the scientific and technical issues associated with complex patent and trade secret matters.


  • Chinese


Bar Admissions

  • New York

*Admitted in New York only; supervised by principals of the Firm; not admitted in California.

Registered to Practice

  • US Patent & Trademark Office


  • St. John’s University, J.D.
  • University of Georgia, Ph.D., Pharmacy
  • University of Science and Technology of China, B.S., Chemistry

Litigation Experience

  • Representing an international biopharmaceutical company in trade secret litigation relating to technologies for developing biosimilar drug products
  • Representing an international pharmaceutical company in Hatch-Waxman litigation relating to compound and formulation patents covering marketed oncology drug product
  • Represented an international pharmaceutical company against multiple generic challengers on formulation patents related to breast cancer treatment